🕒 Last update: loading…

Stock Vera Therapeutics, Inc. VERA

Vera Therapeutics, Inc. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2021 → 2022: -27.58%

Price change 2022 → 2023: -20.52%

Price change 2023 → 2024: 174.97%

Price change 2024 → 2025: 19.74%

Price change 2025 → 2026: -38.80%

Price change 2026 (year to date): -36.26%

Financial growth

Revenue CAGR (7 years): N/A

Earnings CAGR (7 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.13

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -5.19

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 31.19% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Vera Therapeutics, Inc.–0.13–🔒
Vir Biotechnology, Inc.–0.24+115.2 %–
Addus HomeCare Corporation18.60.19+11.7 %★ 4/5
Fleury S.A.16.31.05+16.2 %–
Emeis–6.11+11.4 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Accounts and financial health

Balance sheet and cash flow published by Vera Therapeutics, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
3.62
safe zone (above 2.99)
Piotroski Score
3 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
-0.05 x
net cash
Fiscal year20212022202320242025
Cash and investments79.7 m115 m161 m641 m715 m
Total Debt4.9 m31.3 m53.7 m54.6 m77.3 m
Net Debt-74.8 m-12.2 m8.0 m-38.0 m-277 m
Equity69.6 m76.9 m102 m577 m605 m
Total assets83.7 m131 m176 m656 m735 m
Operating cash flow-23.7 m-67.6 m-92.2 m-135 m-241 m
Investments (capex)062,00063,000972,000630,000
Free cash-flow-23.7 m-67.7 m-92.2 m-136 m-242 m
Share buybacks00013,0000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-4.53 x
Price / book value5.79 x
Return on Equity (ROE)-90.0 %
Return on Invested Capital (ROIC)-104.3 %
Net margin-4,041.2 %
Debt / equity0.23 x
Current ratio7.91 x
Interest coverage-57.40 x
Free cash-flow yield-19.4 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Analyst consensus and forecasts

What the financial analysts covering Vera Therapeutics, Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
14 analysts
Average price target
54.00 USD
from n/a to n/a, 17 targets over 12 months
Gap with the share price
+92.2 %
price 28.10 USD on 13/11/2026

Breakdown of ratings

strong buy 1buy 12hold 1sell 0strong sell 0

Average target over the last 3 months: 54.00 USD (4 targets).

Track record against expectations: reported EPS above consensus 3 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

Vera Therapeutics, Inc.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

DatePublished EPSExpected EPSSurprise
05/11/2026-1.30-1.62n/a
10/08/2026-1.52-1.58n/a
07/05/2026-1.69-1.33n/a
26/02/2026-1.39-1.34n/a
05/11/2025-1.26-1.20n/a
05/08/2025-1.20-0.82n/a

Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Vera Therapeutics, Inc.

Large funds tracked
20
hold the stock as of 2026Q2
Executives (insiders)
0 / 10
0 purchases, 10 sales in 130 days

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
State Street8.3 m356 m0.0 %+146.7 %2026Q2
BlackRock5.7 m247 m0.0 %+13.0 %2026Q2
Vanguard Group3.6 m181 m0.0 %+11.9 %2025Q4
T. Rowe Price4.0 m172 m0.0 %-12.3 %2026Q2
Morgan Stanley2.8 m120 m0.0 %+659.2 %2026Q2
Fidelity2.8 m119 m0.0 %+3.6 %2026Q2
Geode Capital Management1.7 m72.6 m0.0 %+7.8 %2026Q2
Goldman Sachs1.4 m59.3 m0.0 %+21.8 %2026Q2

Latest insider transactions

DatePersonSideAmount
15/09/2026Fordyce Marshallsale684,500 USD
02/09/2026Fordyce Marshallsale649,642 USD
07/07/2026Fordyce Marshallsale40,776 USD
07/07/2026Fordyce Marshallsale1.4 m USD
07/07/2026Fordyce Marshallsale450,007 USD
07/07/2026Fordyce Marshallsale95,908 USD

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 20/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 14/05/2021
ISIN code
US92337R1014
Workforce
152
full-time employees
Chief executive
Marshall W. Fordyce

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Vera Therapeutics, Inc.

What is the Vera Therapeutics, Inc. share price?

Latest recorded price: 28.10 USD on 13/11/2026, for a market cap of 2.0 bn USD.

What do analysts say about Vera Therapeutics, Inc.?

Out of 14 analysts: 13 buy or strong buy, 1 hold, 0 sell or strong sell. Average price target: 54.00 USD, i.e. +92.2 % from the share price.

Is Vera Therapeutics, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US92337R1014).

How many employees does Vera Therapeutics, Inc. have?

152 full-time employees according to the latest published profile.

Who runs Vera Therapeutics, Inc.?

Marshall W. Fordyce is the company's chief executive.

Which large funds own Vera Therapeutics, Inc.?

As of 2026Q2, among the large funds tracked: State Street, BlackRock, Vanguard Group, T. Rowe Price, Morgan Stanley.

07

Similar stocks